A simple and reproducible prognostic index in luminal ER-positive breast cancers by I. Castellano et al.
Annals of Oncology 24: 2292–2297, 2013
doi:10.1093/annonc/mdt183
Published online 24 May 2013
A simple and reproducible prognostic index in luminal
ER-positive breast cancers
I. Castellano1*, L. Chiusa1, A. M. Vandone2, S. Beatrice2, M. Goia1, M. Donadio2, R. Arisio3,
F. Muscarà4, A. Durando4, G. Viale5, P. Cassoni1 & A. Sapino1
1Department of Medical Sciences, University of Turin, Turin; 2Division of Oncology, Centro Oncologico Subalpino (COES), Città della Salute e della Scienza, Turin;
Departments of 3Pathology; 4Obstetrics and Gynaecology, Città della Salute e della Scienza, Sant’Anna Hospital, Turin; 5Division of Pathology and Laboratory Medicine,
European Institute of Oncology, University of Milan, Milan, Italy
Received 10 January 2013; revised 4 April 2013; accepted 5 April 2013
Background: The group of estrogen receptor (ER)-positive breast cancers (both luminal-A and -B) behaves differently
from the ER-negative group. At least in early follow-up, ER expression inﬂuences positively patients’ prognosis. This low
aggressive biology ﬂattens out the differences of clinical management. Thus we aimed to produce a prognostic index
speciﬁc for ER-positive (ERPI) cancers that could be of aid for clinical decision.
Patients and methods: The test set comprised 495 consecutive ER-positive breast cancers. Tumor size, number of
metastatic lymph nodes and androgen receptor expression were the only independent variables related to disease-
speciﬁc survival. These variables were used to create the ERPI, which was applied to the entire test set and to selected
subpopulations (grade 2 (G2)-tumors, luminal-A and -B breast cancers). A series of 581 ER-positive breast cancers,
collected from another hospital, was used to validate ERPI.
Results: In the test population, 96.9% of patients classiﬁed as ERPI-good showed a good prognosis compared with
79.6% classiﬁed as ERPI-poor (P < 0.001). ERPI effectively discriminated outcome in luminal-A and luminal-B and in G2-
tumors. In the validation series, the ERPI maintained its value.
Conclusion: ERPI is a practical tool in reﬁning the prediction of outcome of patients with ER-positive breast cancer.
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introduction
The therapy of estrogen receptor alpha (ER)-positive breast
cancers, which represent more than 70% of breast tumors, is
based on anti-hormonal compounds. ER-positive breast
cancers, as a uniﬁed group, have in general a better prognosis
than the ER-negative group [1]. Within this group, the
prognosis is mainly related to pathological parameters.
However, the prognostic value of grade of differentiation,
vascular invasion, HER2 expression and Ki67 counting may be
undermined by poor reproducibility [2–5]. In addition, in some
cases, parameters of aggressiveness are associated with
parameters of good prognosis (e.g. the presence of metastatic
lymph nodes in an otherwise well-differentiated G1 tumor).
More frequently, one or more of these risk factors are borderline
(e.g. G2 tumor; equivocal HER2 expression; borderline HER2-
gene status, borderline proliferation index), leading to
uncertainty about the tumor behavior, which in turn impairs
the ability to reach informed treatment decisions. So far, several
prognostic indexes (PI), such as the Nottingham Prognostic
Index (NPI) [6–9] and the Adjuvant! Online [10, 11] have been
developed and validated. The NPI was created in 1982 using a
weighted score of three independent variables (tumor size, grade
and number of involved lymph nodes). In the ﬁrst edition of
NPI, patients were classiﬁed into three categories of risk [6];
later on, patients were classiﬁed into six NPI risk categories [8].
Adjuvant! Online is a web-based tool designed to provide
10-year survival probability of patients with breast cancer as a
continuous variable [10]. Strictly, Adjuvant! does consider ER
status (positive/negative) as one of its basic parameters.
We aimed to develop a PI purely within the ER-positive
breast cancers, hypothesizing that classical and new (androgen
receptor: AR) prognostic parameters could have a different
weight in patient outcome when compared with that seen in
HER2-positive and triple negative breast cancers. We
introduced AR because it is expressed in ∼70% of ER-positive
breast cancers and positively affects the outcome of patients as a
possible tumor suppressor [12, 13]. We constructed a weighted
risk score by multivariate analysis of parameters correlated with
disease-speciﬁc survival (DSS) and, from this, we created a PI
able to subdivide patients in two risk categories of good and
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poor prognoses. Finally, we validated the results in an
independent series of ER-positive breast cancers.
patients andmethods
study design and population
A series of 543 patients diagnosed with ER-positive breast cancer between
1994 and 2005 was collected at the Breast Unit of the San Giovanni Battista-
Molinette Hospital of Turin, Italy, of these, 385 patients were part of a
previous recently published study [12].
Sections of the 158 newly collected tumors were reviewed. Multicore
tissue microarrays (TMAs), prepared as previously described [14], were
retested by immunohistochemistry (IHC) for ER-status; 48 of 543 tumors
were ER-negative. These cases, conﬁrmed as negative by IHC carried out on
whole tissue sections, were excluded from the study. The medical charts of
the remaining 495 patients (test series) were reviewed and updated.
A cohort of 581 ER-positive breast cancers centrally reviewed and
collected in the same period from OIRM Sant’Anna Hospital of Turin, Italy,
was used as ‘validation series’ (supplementary Table S1, available at Annals
of Oncology online).
IHC was carried out as previously reported [12], to assess AR (mouse
monoclonal antibody (mAb) clone AR441, Dako, Glostrup, Denmark), ER
(rabbit mAb, clone SP1, Ventana-Diapath, Tucson, AZ) and progesterone
receptor (PR) (rabbit mAb, clone 1E2, Ventana-Diapath). The proliferation
index was assessed using the Ki67 mouse mAb (clone MIB-1, Dako). HER2
status was evaluated using the Herceptest™ (Kit Dako). Equivocal (score 2+)
cases were investigated by FISH assay (Vysis, Inc., Downers Grove, IL).
The cut-off value for ER- and PR-positivity was set at 1%, and the same
cut-off was also adopted for AR-positivity [12]. The percentage of Ki67-
positive cells was counted at the section periphery.
statistical analysis and construction of the
prognostic index
The follow-up time was calculated using the median observation time
among all patients. The follow-up was censored at the time of death or of the
last clinical investigation of the patient. DSS was calculated from the date of
deﬁnitive surgery to the date of death from the disease. Patients dying from
other causes were censored at the time of death. In the test series of 495
patients, DSS was studied using the Kaplan–Meier method and the Log-rank
test (supplementary Figure S1, available at Annals of Oncology online). The
clinical and pathological parameters used for univariate analysis are reported
in supplementary Table S2, available at Annals of Oncology online. The best
cut-off value of tumor size was established at 15 mm [15–20]. For the
multivariable analysis, prognostic factors were selected based on their
statistical signiﬁcance at univariate analysis. ACox proportional hazard
model was used and the effect of single variables was expressed as hazard
ratio (HR) with 95% conﬁdence interval (95% CI). Three covariates
maintained their statistical signiﬁcance: tumor size, number of metastatic
lymph nodes and AR status. A score was attributed to each variable
according to its HR. Its weight value was approximately twofold for tumor
size and AR than for number of metastatic lymph nodes (supplementary
Table S3, available at Annals of Oncology online). Thus, a score value of 2
was given to tumors >15 mm and to tumors with AR-negative. Instead,
tumors ≤15 mm and tumors with AR-positive were scored as 0. Three score
values were used for lymph nodes (0: lymph nodes free of metastases; 1:
from 1 to 3 metastatic lymph-nodes and 2: >3 metastatic lymph nodes).
A PI for ER-positive cancers (ERPI) was created using the following
formula: (tumor size score value) + (number of metastatic lymph nodes
score value) + (AR score value) (Table 1). The two extremes of the ERPI
were 0 and 6. Kaplan–Meier analysis was then carried out for each ERPI
value (Figure 1A). Following the performance curves, we set the cut-off of
the ERPI at 3: value ≤3 good prognosis (ERPI-good), value >3 poor
prognosis (ERPI-poor) (Figure 1B).
A univariate analysis was carried out to study the effect of the ERPI in the
entire test population and in selected subpopulations, namely G2 tumors,
luminal-A and luminal-B cancers. The distinction between luminal-A and
luminal-B was deﬁned according to the proliferation rate by Ki67 (cut-off of
14%) and to HER2-status [21].
To validate the results, we applied the ERPI to the case series from
Sant’Anna Hospital.
Receiver-operating characteristic (ROC) curve analysis was used to
evaluate the ERPI performance in predicting DSS by comparing its value
with other single prognostic factors.
SPSS version 17 (SPSS, Inc., Chicago, IL) software, the R environment
(www.r-project.org), SAS version 9.1 (SAS Institute, Cary, NC) and
S-PLUS version 6.1 (Insightful Corp., Seattle, WA) were used for statistical
analyses.
results
descriptive analyses of the test and the validation
cohorts
The median follow-up time was 7.8 years. The comparison of
the two cohorts of patients (supplementary Table S1, available
at Annals of Oncology online) revealed some differences in the
type of treatment (surgery, radiotherapy and chemotherapy),
probably because of the differences in the size of tumors and
presence of vascular invasion.
ERPI results on the test cohort
At univariate analysis age, treatment type, ER expression levels
and HER2-status did not show any signiﬁcant correlation with
DSS. At multivariate analysis only tumor size, number of
metastatic lymph nodes and AR status resulted signiﬁcant for
prognosis (supplementary Tables S2–S3, available at Annals of
Oncology online). The ERPI, built on the basis of the HR, was
applicable to 385 patients, 92.5% of whom were censored at
follow-up.
The rate of patients censored for ERPI-good was 96.9% and
79.6% for ERPI-poor, with a highly signiﬁcant difference
(χ2 = 40.037, P < 0.001) (Figure 1B, supplementary Table S4,
available at Annals of Oncology online). ERPI maintained its
statistical signiﬁcance both in patients that received hormonal
Table 1. Algorithm to calculate the ERPI
Status Points
Number of metastatic lymph nodes 0 0
1–3 1
>3 2
Tumor size <15 mm 0
>15 mm 2
Androgen receptor 0% 2
≥1% 0
Algorithm: (tumor size score value) + (number of metastatic lymph nodes
score value) + (AR score value).
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Figure 1. Kaplan–Meier analysis carried out on test cohort for each ERPI value (A). Kaplan–Meier analysis carried out for ERPI value using a cut-off of 3: a
value ≤3 was considered as ERPI-good and a value >3 as ERPI-poor (B). ERPI on G2 (C), luminal-A (D) luminal-B and luminal-B HER2-negative cases (E, F).
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therapy and in those treated with hormonal plus chemotherapy
(χ2 = 13.543, P < 0.001 and χ2 = 19.375, P < 0.001 respectively).
ERPI in G2 breast cancer patients
Among 495 breast cancers, 197 (40%) were classiﬁed as G2.
ERPI, assessable in 160 cases, discriminated two populations
with different outcomes (χ2 = 14.179, P < 0.001) (Figure 1C).
As for the entire population, ERPI had a signiﬁcant
correlation with outcome both in the subset of patients treated
with endocrine therapy or with the addition of chemotherapy
(χ2 = 5.169, P = 0.023 and χ2 = 7.422, P = 0.006).
ERPI in luminal-a and luminal-b breast cancer
patients
The signiﬁcant correlation with DSS of ERPI-good and -poor
was maintained in both luminal-A and luminal-B tumors
(χ2 = 8.334, P = 0.004 and χ2 = 23.974, P < 0.001) (Figure 1D–E).
In luminal-A cancers receiving only endocrine therapy, ERPI
discriminated patients with poor outcome (χ2 = 19.273,
P < 0.001), while all patients receiving chemotherapy resulted
censored. In luminal-B cases, ERPI discriminated patients with
poor outcome only in the chemotherapy-treated subgroup
(χ2 = 15.688, P < 0.001). Furthermore, ERPI was effective only in
the luminal-B HER2-negative/Ki67 >14% cancers (χ2 = 20.721,
P < 0.001) (Figure 1F) and not in those HER2-positive (data not
shown).
ERPI conﬁrmed its prognostic value in the validation series
(Figure 2). The DDS for luminal-A cancers that received
endocrine therapy alone was 100% (supplementary Table S5,
available at Annals of Oncology online).
ERPI was more powerful in predicting survival then each
individual parameter in both populations (supplementary
Figure S2, available at Annals of Oncology online).
discussion
In contrast with other PIs that have been created for breast
cancer in general [6, 10, 11], in the present work, we produced a
PI speciﬁc for luminal cancers. In this cancer subset, ERPI
discriminates between patients with good and poor prognoses
as a binary system, whereas other PIs, such as NPI, deﬁne
intermediate risk categories, as well [6, 8].
The ERPI can be constructed from routine diagnosis being
largely based on tumor size and number of lymph node
involvement. We added the expression of AR, because our
group [12] and other authors [13, 22–24] demonstrated the
prognostic relevance of its expression in breast cancers. To our
knowledge, ERPI is the ﬁrst tool of risk evaluation, which
encompasses AR-expression. The IHC reproducibility of AR is
easy to achieve, because we classiﬁed cases as negative or
positive using a cut-off value of 1%, as previously suggested [12].
Regarding tumor size and lymph-nodal status, they are
considered independent prognostic variables [25], both of them
have a good reproducibility and, among various ‘biological
markers’ of prognosis, they may be considered ‘time-dependent
markers’. This means that, in the majority of cancers and in
particular in low aggressive ER-positive tumors, these two
factors are correlated with the lapse of time between tumor
initiation and its diagnosis. Warwick et al. [26] in a study
evaluating the time-dependent effects on breast cancer survival,
suggested that tumor grade, lymph-nodal status, and tumor size
at the time of diagnosis have a lasting inﬂuence on subsequent
survival, albeit attenuated in later years.
In the present study, we deﬁned a tumor size of 15 mm as the
cut-off value to be used in multivariate analysis, based on our
experience [17] and on literature data [15, 16, 18–20]. For
example an analysis of a large series of breast cancers showed
that patient prognosis was very good for tumors up to 14 mm
but was signiﬁcantly worse for larger tumors [19]. Another
study on early breast cancer patients demonstrated, by a
complex mathematical model, that the relative increase in
mortality was considerably higher for each millimeter
increment in the size of smaller tumors than in larger tumors
and that the transition occurred at ∼15 mm [20]. In the same
series, the node-positive status did not abolish the effect of
tumor size.
As reported in a detailed review on tumor-related prognostic
factors for breast cancer, the lymph-nodal status is the single
most inﬂuential predictor of post-treatment recurrence and
death [27]. However, rather than the node involvement, the
absolute number of metastatic nodes is related to the
prognostic continuum of recurrence and survival [28, 29].
Different studies showed that patients without metastasis and
those with one to three metastatic lymph nodes have similar
outcomes [16, 30, 31]. On the other hands, extensive lymph-
nodal involvement (>3 involved nodes) is considered an
indication to chemotherapy regardless of the biological breast
cancer subset [21]. Taking together all these data reinforce our
results, which selected the tumor size, the number of lymph
nodes affected by metastases and the AR status parameters as
independent variables. ERPI was helpful for deﬁning
prognosis in G2 tumors, which are both poorly reproducible as
an entity and poorly deﬁned in their outcome. The ERPI
identiﬁed patients with different prognoses even in luminal-A
tumors, which are considered to have an indolent outcome, so
that after being surgically removed, they could skip further
treatment or be treated with endocrine therapy only [21].
Nevertheless, in our study, 19% (test series) and 49% (validation
series) of the patients with luminal-A cancers received
chemotherapy in addition to endocrine therapy. These differences
demonstrate the difﬁculty in adopting reproducible criteria for
the therapy decision.
ERPI was also signiﬁcant in the group of luminal-B cancers
with high Ki67 levels that received chemotherapy. High and low
Ki67-labeling indexes provide information regarding the
response to chemotherapy and the prognosis in patients
receiving neoadjuvant treatment of breast cancer [32, 33].
However, mid-range Ki67 levels such as those proposed for
classifying either luminal-A or luminal-B cancers suffer from
poor reproducibility [2]. The ERPI lost its signiﬁcance in ER-
positive/HER2-positive breast cancers.
The ERPI may indeed offer several advantages, including the
easy application to formalin-ﬁxed and parafﬁn-embedded tissue
and the use of standardized parameters, commonly adopted in
the diagnosis of breast cancer. The ERPI may thus represent a
valuable tool in reﬁning the prognosis in patients with
ER-positive breast cancer.
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Figure 2. Kaplan–Meier analysis carried out on validation cohort for each ERPI value (A). Kaplan–Meier analysis carried out for ERPI value using a cut-off of
3: a value ≤3 was considered as ERPI-good and a value >3 ERPI-poor (B). ERPI on G2 (C), luminal-A (D) luminal-B and luminal-B HER2 negative cases (E, F).
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